(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Cheetah Mobile, Chegg, and JP Morgan Chase.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Cheetah Mobile (CMCM) | 2.80 | 15.7% | 2023-04-14 03:11:07 |
| 2 | Chegg (CHGG) | 17.99 | 7.27% | 2023-04-13 23:48:07 |
| 3 | JP Morgan Chase (JPM) | 138.13 | 7.09% | 2023-04-14 13:41:50 |
| 4 | Cemex, S.A.B. de C.V. Sponsored ADR (CX) | 6.00 | 6.01% | 2023-04-14 07:46:08 |
| 5 | Quidel (QDEL) | 94.63 | 5.53% | 2023-04-14 13:11:55 |
| 6 | Coeur Mining (CDE) | 4.43 | 5.48% | 2023-04-13 23:06:08 |
| 7 | Coeur Mining (CDE) | 4.43 | 5.48% | 2023-04-13 23:06:08 |
| 8 | Momo (MOMO) | 8.77 | 5.41% | 2023-04-14 12:26:59 |
| 9 | Citigroup (C) | 49.58 | 4.82% | 2023-04-14 13:38:56 |
| 10 | POSCO (PKX) | 77.96 | 4.8% | 2023-04-14 13:19:54 |
The three biggest losers today are Catalent, Nikola, and Qwest Corporation 6.875% Notes due 2054.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Catalent (CTLT) | 45.88 | -27.54% | 2023-04-14 13:17:22 |
| 2 | Nikola (NKLA) | 0.84 | -13.75% | 2023-04-14 13:14:34 |
| 3 | Qwest Corporation 6.875% Notes due 2054 (CTV) | 0.77 | -12.92% | 2023-04-14 07:14:06 |
| 4 | Teva Pharmaceutical (TEVA) | 8.24 | -10.96% | 2023-04-14 13:45:17 |
| 5 | Xenetic Biosciences (XBIO) | 0.46 | -8.89% | 2023-04-14 12:16:24 |
| 6 | Inovio Pharmaceuticals (INO) | 0.86 | -8.13% | 2023-04-14 12:26:19 |
| 7 | Emergent Biosolutions (EBS) | 11.69 | -7.41% | 2023-04-14 13:13:09 |
| 8 | Bionano Genomics (BNGO) | 1.08 | -6.9% | 2023-04-14 13:13:35 |
| 9 | U.S. Gold Corp (USAU) | 4.38 | -6.61% | 2023-04-14 13:15:32 |
| 10 | Concord Medical Services Holdings Limited ADS (CCM) | 1.15 | -6.58% | 2023-04-13 22:42:07 |
Winners today
1. Cheetah Mobile (CMCM) – 15.7%
Cheetah Mobile Inc. operates as an internet company in the People's Republic of China, the United States, and internationally. The company's utility products include Clean Master, a junk file cleaning, memory boosting, and privacy protection tool for mobile devices; Security Master, an anti-virus and security application for mobile devices; and Duba Anti-virus, an internet security application to protect users against known and unknown security threats and malicious applications. In addition, it offers mobile games comprising Piano Tiles 2, Rolling Sky, and Dancing Line; and Cheetah GreetBot, a reception robot. Further, the company provides mobile advertising publisher services; duba.com personal start page that aggregates online resources and provides users access to their online destinations; cloud-based data analytics engines; and artificial intelligence and other services. It serves direct advertisers that include mobile application developers, mobile game developers, and e-commerce companies, as well as search engines and partnering mobile advertising networks. The company was formerly known as Kingsoft Internet Software Holdings Limited and changed its name to Cheetah Mobile Inc. in March 2014. Cheetah Mobile Inc. was incorporated in 2009 and is headquartered in Beijing, the People's Republic of China.
NYSE ended the session with Cheetah Mobile rising 15.7% to $2.80 on Friday, following the last session’s upward trend. NYSE slid 0.19% to $15,601.78, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Cheetah Mobile has a trailing twelve months EPS of $-2.9.
Sales Growth
Cheetah Mobile’s sales growth is negative 46.4% for the ongoing quarter and negative 46.4% for the next.
Yearly Top and Bottom Value
Cheetah Mobile’s stock is valued at $2.80 at 17:32 EST, way under its 52-week high of $6.50 and way higher than its 52-week low of $1.41.
Volume
Today’s last reported volume for Cheetah Mobile is 136778 which is 287.8% above its average volume of 35270.
More news about Cheetah Mobile.
2. Chegg (CHGG) – 7.27%
Chegg, Inc. operates direct-to-student learning platform that supports students on their journey from high school to college and into their career with tools designed to help them to learn their course materials, succeed in their classes, and save money on required materials. The company offers Chegg Services, which include subscription services; and required materials that comprise its print textbooks and eTextbooks. Its subscription services include Chegg Study, which helps students master challenging concepts on their own; Chegg Writing that provides students with a suite of tools, such as plagiarism detection scans, grammar and writing fluency checking, expert personalized writing feedback, and premium citation generation; Chegg Math solver, a step-by-step math problem solver and calculator that helps students to solve problems; Chegg Study Pack, a bundle of various Chegg Services product offerings, including Chegg Study, Chegg Writing, Chegg Math Solver, video content, and practice quizzes, which creates an integrated platform of connected academic support services; and Thinkful, a skills-based learning platform that offers professional courses in the areas of software engineering, UX/UI design, digital marketing, data science, product management, data analytics, product design, and technical project management directly to students. The company also provides other services, such as Chegg Prep and internships; and rents and sells print textbooks and eTextbooks. Chegg, Inc. was incorporated in 2005 and is headquartered in Santa Clara, California.
NYSE ended the session with Chegg rising 7.27% to $17.99 on Friday while NYSE fell 0.19% to $15,601.78.
Earnings Per Share
As for profitability, Chegg has a trailing twelve months EPS of $1.37.
PE Ratio
Chegg has a trailing twelve months price to earnings ratio of 13.13. Meaning, the purchaser of the share is investing $13.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.98%.
Moving Average
Chegg’s value is above its 50-day moving average of $16.71 and way below its 200-day moving average of $21.38.
Yearly Top and Bottom Value
Chegg’s stock is valued at $17.99 at 17:32 EST, way below its 52-week high of $32.65 and way higher than its 52-week low of $15.25.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Chegg’s EBITDA is 992.74.
Volume
Today’s last reported volume for Chegg is 4950160 which is 58.31% above its average volume of 3126790.
More news about Chegg.
3. JP Morgan Chase (JPM) – 7.09%
JPMorgan Chase & Co. operates as a financial services company worldwide. It operates through four segments: Consumer & Community Banking (CCB), Corporate & Investment Bank (CIB), Commercial Banking (CB), and Asset & Wealth Management (AWM). The CCB segment offers deposit, investment and lending products, cash management, and payments and services to consumers and small businesses; mortgage origination and servicing activities; residential mortgages and home equity loans; and credit cards, auto loans, leases, and travel services. The CIB segment provides investment banking products and services, including corporate strategy and structure advisory, and equity and debt markets capital-raising services, as well as loan origination and syndication; payments and cross-border financing; and cash and derivative instruments, risk management solutions, prime brokerage, and research. This segment also offers securities services, including custody, fund accounting and administration, and securities lending products for asset managers, insurance companies, and public and private investment funds. The CB segment provides financial solutions, including lending, payments, investment banking, and asset management to small and midsized companies, local governments, nonprofit clients, and large corporations; and commercial real estate banking services to investors, developers, and owners of multifamily, office, retail, industrial, and affordable housing properties. The AWM segment offers multi-asset investment management solutions in equities, fixed income, alternatives, and money market funds to institutional clients and retail investors; and retirement products and services, brokerage, custody, estate planning, lending, deposits, and investment management products. The company also provides ATM, online and mobile, and telephone banking services. JPMorgan Chase & Co. was founded in 1799 and is headquartered in New York, New York.
NYSE ended the session with JP Morgan Chase rising 7.09% to $138.13 on Friday, following the last session’s upward trend. NYSE slid 0.19% to $15,601.78, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, JP Morgan Chase has a trailing twelve months EPS of $12.09.
PE Ratio
JP Morgan Chase has a trailing twelve months price to earnings ratio of 11.43. Meaning, the purchaser of the share is investing $11.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.85%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 30.8% and 18.5%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.6%, now sitting on 122.31B for the twelve trailing months.
More news about JP Morgan Chase.
4. Cemex, S.A.B. de C.V. Sponsored ADR (CX) – 6.01%
CEMEX, S.A.B. de C.V., together with its subsidiaries, produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, clinker, and other construction materials worldwide. The company also offers various complementary construction products, including asphalt products; concrete blocks; roof tiles; architectural products; concrete pipes for storm and sanitary sewers applications; and other precast products, such as rail products, concrete floors, box culverts, bridges, drainage basins, barriers, and parking curbs. In addition, it provides building solutions for housing projects, pavement projects, and green building consultancy services; cement trade maritime services; and information technology solutions. The company operates approximately 2,000 retail stores in approximately 600 cities. CEMEX, S.A.B. de C.V. was founded in 1906 and is headquartered in San Pedro Garza GarcÃa, Mexico.
NYSE ended the session with Cemex, S.A.B. de C.V. Sponsored ADR rising 6.01% to $6.00 on Friday while NYSE fell 0.19% to $15,601.78.
Earnings Per Share
As for profitability, Cemex, S.A.B. de C.V. Sponsored ADR has a trailing twelve months EPS of $0.37.
PE Ratio
Cemex, S.A.B. de C.V. Sponsored ADR has a trailing twelve months price to earnings ratio of 16.22. Meaning, the purchaser of the share is investing $16.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.3%.
Moving Average
Cemex, S.A.B. de C.V. Sponsored ADR’s worth is way above its 50-day moving average of $5.23 and way higher than its 200-day moving average of $4.38.
Sales Growth
Cemex, S.A.B. de C.V. Sponsored ADR’s sales growth is 4.7% for the ongoing quarter and 2.5% for the next.
More news about Cemex, S.A.B. de C.V. Sponsored ADR.
5. Quidel (QDEL) – 5.53%
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
NASDAQ ended the session with Quidel rising 5.53% to $94.63 on Friday, following the last session’s upward trend. NASDAQ fell 0.35% to $12,123.47, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Quidel has a trailing twelve months EPS of $9.61.
PE Ratio
Quidel has a trailing twelve months price to earnings ratio of 9.85. Meaning, the purchaser of the share is investing $9.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.19%.
Volume
Today’s last reported volume for Quidel is 811999 which is 88.48% above its average volume of 430809.
Revenue Growth
Year-on-year quarterly revenue growth grew by 53.7%, now sitting on 3.04B for the twelve trailing months.
Sales Growth
Quidel’s sales growth is 22.4% for the ongoing quarter and negative 27.6% for the next.
More news about Quidel.
6. Coeur Mining (CDE) – 5.48%
Coeur Mining, Inc. explores for, develops, produces, and sells precious metals in the United States, Canada, and Mexico. The company primarily explores for gold, silver, zinc, and lead properties. It holds 100% interests in the Palmarejo gold and silver mine covering an area of approximately 67,296 net acres located in the State of Chihuahua in Northern Mexico; the Rochester silver and gold mine that covers an area of approximately 17,044 net acres situated in northwestern Nevada; the Kensington gold mine comprising 12,336 net acres located to the north of Juneau, Alaska; the Wharf gold mine covering an area of approximately 7,852 net acres situated in the northern Black Hills of western South Dakota; and the Silvertip silver-zinc-lead mine comprising 98,834 net acres located in northern British Columbia, Canada. The company also owns interests in the Crown and Sterling projects located in southern Nevada; and the La Preciosa project located in Mexico. It markets and sells its concentrates to third-party refiners, smelters, and off-take customers. The company was formerly known as Coeur d'Alene Mines Corporation and changed its name to Coeur Mining, Inc. in May 2013. Coeur Mining, Inc. was incorporated in 1928 and is headquartered in Chicago, Illinois.
NYSE ended the session with Coeur Mining jumping 5.48% to $4.43 on Friday while NYSE slid 0.19% to $15,601.78.
Earnings Per Share
As for profitability, Coeur Mining has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.25%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 20% and 20%, respectively.
Sales Growth
Coeur Mining’s sales growth is negative 3.5% for the current quarter and negative 8.1% for the next.
Volume
Today’s last reported volume for Coeur Mining is 6367030 which is 15.6% above its average volume of 5507760.
More news about Coeur Mining.
7. Coeur Mining (CDE) – 5.48%
Coeur Mining, Inc. explores for, develops, produces, and sells precious metals in the United States, Canada, and Mexico. The company primarily explores for gold, silver, zinc, and lead properties. It holds 100% interests in the Palmarejo gold and silver mine covering an area of approximately 67,296 net acres located in the State of Chihuahua in Northern Mexico; the Rochester silver and gold mine that covers an area of approximately 17,044 net acres situated in northwestern Nevada; the Kensington gold mine comprising 12,336 net acres located to the north of Juneau, Alaska; the Wharf gold mine covering an area of approximately 7,852 net acres situated in the northern Black Hills of western South Dakota; and the Silvertip silver-zinc-lead mine comprising 98,834 net acres located in northern British Columbia, Canada. The company also owns interests in the Crown and Sterling projects located in southern Nevada; and the La Preciosa project located in Mexico. It markets and sells its concentrates to third-party refiners, smelters, and off-take customers. The company was formerly known as Coeur d'Alene Mines Corporation and changed its name to Coeur Mining, Inc. in May 2013. Coeur Mining, Inc. was incorporated in 1928 and is headquartered in Chicago, Illinois.
NYSE ended the session with Coeur Mining jumping 5.48% to $4.43 on Friday, after three sequential sessions in a row of gains. NYSE dropped 0.19% to $15,601.78, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Coeur Mining has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.25%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 20% and 20%, respectively.
Yearly Top and Bottom Value
Coeur Mining’s stock is valued at $4.43 at 17:32 EST, way below its 52-week high of $5.40 and way higher than its 52-week low of $2.54.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 785.64M for the twelve trailing months.
More news about Coeur Mining.
8. Momo (MOMO) – 5.41%
Hello Group Inc. provides mobile-based social and entertainment services in the People's Republic of China. It operates Momo platform that includes its Momo mobile application, as well as various related properties, features, functionalities, tools, and services. The company's Momo mobile application connects people and facilitates interactions based on location and interests; and various recreational activities, including live talent shows, short videos, and social games, as well as other video- and audio-based interactive experiences, such as online parties, mobile karaoke, and user participated reality shows. It also operates Tantan, a social and dating application, which enables users to find and establish romantic connections, and meet interesting people; and provides live video, quick chat, value-added, mobile marketing, and other services, as well as mobile games and audio chatrooms. In addition, it allows its platform's users to livestream a variety of content and activities that comprise talent shows, such as singing, dancing, and talk shows, as well as casual chatting, and other forms of interactions between broadcasters and viewers. The company was formerly known as Momo Inc. and changed its name to Hello Group Inc. in August 2021. Hello Group Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.
NASDAQ ended the session with Momo rising 5.41% to $8.77 on Friday, following the last session’s upward trend. NASDAQ fell 0.35% to $12,123.47, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, Momo has a trailing twelve months EPS of $1.04.
PE Ratio
Momo has a trailing twelve months price to earnings ratio of 8.43. Meaning, the purchaser of the share is investing $8.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.97%.
Sales Growth
Momo’s sales growth is negative 8% for the present quarter and negative 2.8% for the next.
Moving Average
Momo’s value is under its 50-day moving average of $9.44 and way above its 200-day moving average of $6.64.
More news about Momo.
9. Citigroup (C) – 4.82%
Citigroup Inc., a diversified financial services holding company, provides various financial products and services to consumers, corporations, governments, and institutions in North America, Latin America, Asia, Europe, the Middle East, and Africa. It operates through three segments: Institutional Clients Group (ICG), Personal Banking and Wealth Management (PBWM), and Legacy Franchises. The ICG segment offers wholesale banking products and services, including fixed income and equity sales and trading, foreign exchange, prime brokerage, derivative, equity and fixed income research, corporate lending, investment banking and advisory, private banking, cash management, trade finance, and securities services to corporate, institutional, and public sector clients. The PBWM segment offers traditional banking services to retail and small business customers through retail banking, cash, rewards, value portfolios, and co-branded cards. It also provides various banking, credit cards, custody, trust, mortgages, home equity, small business, and personal consumer loans. The Legacy Franchises segment provides traditional retail banking and branded card products to retail and small business customers. The company was founded in 1812 and is headquartered in New York, New York.
NYSE ended the session with Citigroup rising 4.82% to $49.58 on Friday, following the last session’s upward trend. NYSE slid 0.19% to $15,601.78, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Citigroup (c) beats Q1 earnings and revenue estimatesWhile Citigroup has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
Citigroup (c) Q1 earnings & revenues beat estimates, costs upIn the reported quarter, Citigroup returned $1 billion to shareholders in the form of common share dividends., Progressing with its global consumer banking exits, in first-quarter Citigroup announced the completion of the sale of its Vietnam retail banking and consumer credit card businesses to United Overseas Bank Limited or UOB.
Here's what key metrics tell us about Citigroup (c) Q1 earningsHere is how Citigroup performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Citigroup has a trailing twelve months EPS of $7.11.
PE Ratio
Citigroup has a trailing twelve months price to earnings ratio of 6.97. Meaning, the purchaser of the share is investing $6.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.5%.
Volatility
Citigroup’s last week, last month’s, and last quarter’s current intraday variation average was 0.78%, 0.05%, and 1.47%.
Citigroup’s highest amplitude of average volatility was 1.08% (last week), 1.51% (last month), and 1.47% (last quarter).
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 2, 2023, the estimated forward annual dividend rate is 2.04 and the estimated forward annual dividend yield is 3.99%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 17.3% and a negative 28.3%, respectively.
More news about Citigroup.
10. POSCO (PKX) – 4.8%
POSCO Holdings Inc., together with its subsidiaries, manufactures and sells iron and steel rolled products in South Korea and internationally. It operates in two segments Steel and Others. The company offers hot and cold rolled steel, steel plates, wire rods, galvanized steel, electrical steel, stainless steel, and titanium. It is also involved in the e-commerce business; processing and sale of steel by-products; and provision of business support, and office administration and management consulting services. The company serves automotive, construction, shipbuilding, energy, home appliances, and industrial machinery applications. POSCO Holdings Inc. was incorporated in 1968 and is headquartered in Pohang, South Korea.
NYSE ended the session with POSCO rising 4.8% to $77.96 on Friday while NYSE slid 0.19% to $15,601.78.
Earnings Per Share
As for profitability, POSCO has a trailing twelve months EPS of $7.4.
PE Ratio
POSCO has a trailing twelve months price to earnings ratio of 10.54. Meaning, the purchaser of the share is investing $10.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.41%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, POSCO’s stock is considered to be oversold (<=20).
More news about POSCO.
Losers Today
1. Catalent (CTLT) – -27.54%
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
NYSE ended the session with Catalent falling 27.54% to $45.88 on Friday while NYSE fell 0.19% to $15,601.78.
Earnings Per Share
As for profitability, Catalent has a trailing twelve months EPS of $2.2.
PE Ratio
Catalent has a trailing twelve months price to earnings ratio of 20.85. Meaning, the purchaser of the share is investing $20.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 30.8% and positive 20.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.6%, now sitting on 4.76B for the twelve trailing months.
More news about Catalent.
2. Nikola (NKLA) – -13.75%
Nikola Corporation operates as a technology innovator and integrator that works to develop energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery hydrogen-electric and battery-electric semi-trucks to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation is headquartered in Phoenix, Arizona.
NASDAQ ended the session with Nikola falling 13.75% to $0.84 on Friday while NASDAQ slid 0.35% to $12,123.47.
Earnings Per Share
As for profitability, Nikola has a trailing twelve months EPS of $-1.74.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.47%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 87% and a negative 71.4%, respectively.
Sales Growth
Nikola’s sales growth for the next quarter is 2539.1%.
Volume
Today’s last reported volume for Nikola is 42060500 which is 163.57% above its average volume of 15957900.
Previous days news about Nikola
- : three nikola board members to retire in June. According to MarketWatch on Thursday, 13 April, "Electric-vehicle maker Nikola Corp. on Thursday said that Gerrit Marx, Lynn Forester de Rothschild and Mark Russellwere retiring from its board of directors at its annual meeting on June 7. ", "Russell joined Nikola in 2019 as president, became CEO and then retired last year, the company said. "
More news about Nikola.
3. Qwest Corporation 6.875% Notes due 2054 (CTV) – -12.92%
Innovid Corp. operates as a connected TV advertising delivery and measurement platform. It offers marketer solutions, such as connected TV advertising, Ad serving, creative management, advertising measurement, and identity resolution; publisher solutions; and creative Ad authoring tools. The company serves brands, agencies, and publishers in the Americas, Europe, and the Asia Pacific. Innovid Corp. was founded in 2007 and is headquartered in New York, New York.
NYSE ended the session with Qwest Corporation 6.875% Notes due 2054 sliding 12.92% to $0.77 on Friday while NYSE dropped 0.19% to $15,601.78.
Earnings Per Share
As for profitability, Qwest Corporation 6.875% Notes due 2054 has a trailing twelve months EPS of $-0.12.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.03%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Qwest Corporation 6.875% Notes due 2054’s EBITDA is -96.88.
Moving Average
Qwest Corporation 6.875% Notes due 2054’s worth is way under its 50-day moving average of $1.64 and way under its 200-day moving average of $2.40.
Revenue Growth
Year-on-year quarterly revenue growth grew by 29.8%, now sitting on 127.12M for the twelve trailing months.
Sales Growth
Qwest Corporation 6.875% Notes due 2054’s sales growth is 10.2% for the ongoing quarter and negative 6.6% for the next.
More news about Qwest Corporation 6.875% Notes due 2054.
4. Teva Pharmaceutical (TEVA) – -10.96%
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
NYSE ended the session with Teva Pharmaceutical dropping 10.96% to $8.24 on Friday while NYSE dropped 0.19% to $15,601.78.
Earnings Per Share
As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-2.1.
More news about Teva Pharmaceutical.
5. Xenetic Biosciences (XBIO) – -8.89%
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
NASDAQ ended the session with Xenetic Biosciences sliding 8.89% to $0.46 on Friday, following the last session’s upward trend. NASDAQ fell 0.35% to $12,123.47, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.48.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.
More news about Xenetic Biosciences.
6. Inovio Pharmaceuticals (INO) – -8.13%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals falling 8.13% to $0.86 on Friday, after two successive sessions in a row of gains. NASDAQ slid 0.35% to $12,123.47, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.49.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.27%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 66% and 52.8%, respectively.
Yearly Top and Bottom Value
Inovio Pharmaceuticals’s stock is valued at $0.86 at 17:32 EST, below its 52-week low of $0.93.
Sales Growth
Inovio Pharmaceuticals’s sales growth is negative 59.5% for the ongoing quarter and 0.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3038.2%, now sitting on 10.98M for the twelve trailing months.
More news about Inovio Pharmaceuticals.
7. Emergent Biosolutions (EBS) – -7.41%
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
NYSE ended the session with Emergent Biosolutions sliding 7.41% to $11.69 on Friday, following the last session’s upward trend. NYSE slid 0.19% to $15,601.78, following the last session’s upward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, Emergent Biosolutions has a trailing twelve months EPS of $-4.55.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.91%.
Volume
Today’s last reported volume for Emergent Biosolutions is 860923 which is 49.57% below its average volume of 1707430.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Emergent Biosolutions’s EBITDA is -61.47.
Yearly Top and Bottom Value
Emergent Biosolutions’s stock is valued at $11.69 at 17:32 EST, way below its 52-week high of $41.89 and way above its 52-week low of $7.74.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 683.3% and positive 41.9% for the next.
More news about Emergent Biosolutions.
8. Bionano Genomics (BNGO) – -6.9%
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
NASDAQ ended the session with Bionano Genomics falling 6.9% to $1.08 on Friday, following the last session’s upward trend. NASDAQ dropped 0.35% to $12,123.47, following the last session’s upward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, Bionano Genomics has a trailing twelve months EPS of $-0.49.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.5%.
Volume
Today’s last reported volume for Bionano Genomics is 2433410 which is 59.64% below its average volume of 6030190.
Yearly Top and Bottom Value
Bionano Genomics’s stock is valued at $1.08 at 17:32 EST, way below its 52-week high of $4.35 and above its 52-week low of $1.06.
Revenue Growth
Year-on-year quarterly revenue growth grew by 55.1%, now sitting on 25.89M for the twelve trailing months.
More news about Bionano Genomics.
9. U.S. Gold Corp (USAU) – -6.61%
U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 650 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 87 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project that consists of 103 unpatented mining claims covering approximately 3 square miles in Eureka County, Nevada. The company is based in Elko, Nevada.
NASDAQ ended the session with U.S. Gold Corp dropping 6.61% to $4.38 on Friday, following the last session’s upward trend. NASDAQ slid 0.35% to $12,123.47, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, U.S. Gold Corp has a trailing twelve months EPS of $-0.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.57%.
More news about U.S. Gold Corp.
10. Concord Medical Services Holdings Limited ADS (CCM) – -6.58%
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners and emission computed tomograms scanners for diagnostic imaging, electroencephalography for the diagnosis of epilepsy, and ultrasound therapy. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2020, it operated a network of 27 cooperative centers based in 20 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
NYSE ended the session with Concord Medical Services Holdings Limited ADS dropping 6.58% to $1.15 on Friday, after three consecutive sessions in a row of losses. NYSE fell 0.19% to $15,601.78, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Concord Medical Services Holdings Limited ADS has a trailing twelve months EPS of $-1.96.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.63%.
More news about Concord Medical Services Holdings Limited ADS.
Stay up to date with our winners and losers daily report
